Kazia Therapeutics Ltd
ASX:KZA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kazia Therapeutics Ltd
Cash from Financing Activities
Kazia Therapeutics Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kazia Therapeutics Ltd
ASX:KZA
|
Cash from Financing Activities
AU$13m
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
16%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash from Financing Activities
$150.5m
|
CAGR 3-Years
65%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
CSL Ltd
ASX:CSL
|
Cash from Financing Activities
-$2.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-18%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Cash from Financing Activities
AU$9.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash from Financing Activities
-AU$3.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash from Financing Activities
AU$138.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
29%
|
CAGR 10-Years
32%
|
|
Kazia Therapeutics Ltd
Glance View
Kazia Therapeutics Ltd. engages in the development of pharmaceutical drug. The company is headquartered in Sydney, New South Wales. The firm collaborates with clinicians, scientists, and researchers across the world for the development of cancer treatment. The Company’s product candidates include Paxalisib and EVT801. Paxalisib (GDC-0084) is invented by Genentech, Inc (South San Francisco, CA). Genentech, Inc is a developer of new cancer medicines across the world. The firm entered into a license agreement with Genentech. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor. EVT801 is invented by Sanofi SA (Paris, France), and licensed to Evotec SE (Hamburg, Germany). The firm entered into a license agreement with Evotec. EVT801 is ready for Phase I clinical trial.
See Also
What is Kazia Therapeutics Ltd's Cash from Financing Activities?
Cash from Financing Activities
13m
AUD
Based on the financial report for Jun 30, 2023, Kazia Therapeutics Ltd's Cash from Financing Activities amounts to 13m AUD.
What is Kazia Therapeutics Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
16%
Over the last year, the Cash from Financing Activities growth was 248%. The average annual Cash from Financing Activities growth rates for Kazia Therapeutics Ltd have been 2% over the past three years , and 16% over the past ten years .
